Page 1 | Search Results | Blood Advances | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential

Yuto Nakajima, Akihisa Oda, Nemekhbayar Baatartsogt, Yuji Kashiwakura, Tsukasa Ohmori, Keiji Nogami

Blood Adv (2024) 8 (15): 3929–3940.

https://doi.org/10.1182/bloodadvances.2023012391

Published: 2024

Includes: Supplemental data

Journal Articles

Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations

Naruto Shimonishi, Kenichi Ogiwara, Junko Yoshida, Kyoji Horie, Yuto Nakajima, Shoko Furukawa, Masahiro Takeyama, Keiji Nogami

Blood Adv (2023) 7 (12): 2831–2842.

https://doi.org/10.1182/bloodadvances.2022008918

Published: 2023

Includes: Supplemental data

Journal Articles

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential

Yuto Nakajima, Masahiro Takeyama, Akihisa Oda, Naruto Shimonishi, Keiji Nogami

Blood Adv (2023) 7 (8): 1436–1445.

https://doi.org/10.1182/bloodadvances.2022008187

Published: 2023

Includes: Supplemental data

Journal Articles

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma

Makiko Yamasaki-Morita, Yasuyuki Arai, Takashi Ishihara, Tomoko Onishi, Hanako Shimo, Kayoko Nakanishi, Yukiko Nishiyama, Tomoyasu Jo, Hidefumi Hiramatsu, Takaya Mitsuyoshi, Chisaki Mizumoto, Junya Kanda, Momoko Nishikori, Toshio Kitawaki, Keiji Nogami, Akifumi Takaori-Kondo, Miki Nagao, Souichi Adachi

Blood Adv (2022) 6 (14): 4216–4223.

https://doi.org/10.1182/bloodadvances.2022007454

Published: 2022

Includes: Supplemental data

Journal Articles

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami

Blood Adv (2017) 1 (22): 1891–1899.

https://doi.org/10.1182/bloodadvances.2017006684

Published: 2017

Includes: Supplemental data

NARROW

The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential

Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Email alerts

ASH Publications

American Society of Hematology

The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential

Impaired factor V–related anticoagulant mechanisms and deep vein thrombosis associated with A2086D and W1920R mutations

Factor VIII mutated with Lys1813Ala within the factor IXa-binding region enhances intrinsic coagulation potential

Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only